Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Malignant Solid Tumors × TAK-243 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Anemia, Refractory, with Excess of Blasts 1 Advanced Malignant Solid Tumors 1

Interventions

vorolanib 3 neratinib 3 dacomitinib 1 Vinorelbine 1 TAK-243 1 Premedication 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Capecitabine 1 1-(4-(4-(3-oxa-8-azabicyclo(3.2.1)octan-8-yl)-6-morpholino-1,3,5-triazin-2-yl)phenyl)-3-(pyridin-4-yl)urea 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02045095 2019-03-14

A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors

Takeda

Phase 1 Terminated

29 enrolled 25 charts

Other solid neoplasm

Advanced Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡